通过聚合体同时提供抗炎和抗氧化剂,用于骨关节炎治疗
相关实验视频
Updated: Sep 14, 2025

05:50
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
1.3K
Mengjie Rui1, Li Wang1, Ke Mi1
1School of Pharmacy, Jiangsu University, Zhenjiang, Jiangsu, China.
Frontiers in pharmacology
|July 24, 2025
概括
这项研究开发了一种用于骨关节炎治疗的新型聚合体系统,有效地输送皮质素和酸,以减少炎症并促进软骨修复. 在OA大鼠模型中,联合递送系统显示出显著的治疗益处.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨关节炎 (OA) 是一种由炎症和氧化应激为特征的退行性关节疾病.
- 目前的治疗方法往往缺乏有效性或产生副作用.
- 开发先进的药物输送系统对于有效的OA管理至关重要.
研究的目的:
- 创建一个基于聚合体的共递送系统,用于水友性cordycepin和疏水性phenylboronic acid (PBA).
- 提高这些化合物的可溶性,稳定性和治疗疗效,对抗OA.
- 为了优化高封装,持续释放和反应性氧物种 (ROS) 清理的配方参数.
主要方法:
- 使用了Taguchi直角设计来优化配方.
- 在LPS激活的RAW 264.7巨细胞上评估的体外抗炎作用.
- 在帕帕因诱导的OA大鼠模型中评估了体内治疗疗效.
- 监测关节胀和血清细胞因子.
主要成果:
- 优化的共负荷聚合体体测量为101.03 ± 0.42 nm,PDI为0.248 ± 0.014.
- 展示了H2O2响应释放和强大的ROS清理能力.
- 在体外显著减少炎症性细胞因子和ROS.
- 在OA大鼠中显示出最大的软骨损伤减少和促进再生.
结论:
- 联合交付系统提供了持续释放和增强的联合向,减少了不良影响.
- 与单个化合物或它们的组合相比,获得了优异的治疗结果.
- 代表了骨关节炎管理的有前途的治疗策略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drug Delivery: Overview
426
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
426
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
599
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
599
Inflammatory Bowel Disease IV: Pharmacological Management
193
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
193

